YOLFTbeta
FR

Firebrick Pharma Ltd

FRE · AU · Healthcare / Drug Manufacturers - General

0.03AUD-0.00 (-3.23%)

Price History

Full chart

Market Stats

Previous Close0.031
Open0.032
Day Range0.03 – 0.032
52-Week Range0.024 – 0.074
Volume63.24K
Market Cap8.04M
P/E (TTM)0.00
Forward P/E0.00
EPS-0.01
Dividend Yield0.00%
Beta0.85
50-Day Avg0.0287
200-Day Avg0.0454

About

Firebrick Pharma Limited develops and commercializes povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal and throat spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - General
  • CEODr. Peter Laurence Molloy B.Sc., F.A.C.I.D., M.B.A., Ph.D.
  • Employees0
  • HeadquartersLevel 14, Melbourne, VIC, Australia, Australia
  • Websitehttps://firebrickpharma.com

Leadership

  • Dr. Peter Laurence Molloy B.Sc., F.A.C.I.D., M.B.A., Ph.D.Founder, Executive Chairman & CEO · b. 1954
  • Dr. Stephen Francis Goodall M.B.A., Ph.D.Founder, COO & Executive Director
  • Mr. Kavi Bekarma B.Sc., C.A.Chief Financial Officer
  • Dr. Simon Tucker B.Sc., Ph.D.Chief Scientific Officer
  • Dr. Monique Baldwin B.Sc., Ph.D.Head of Regulatory Affairs
  • Mr. Nilesh N. WadhwaHead of Business Development & Licensing · b. 1970
  • Mr. Stephen BuckleyCompany Secretary

Financials

Income Statement

Currency: AUD2019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Revenue0508.98K422.00K4.12K83014.52K293.42K106.03K
Growth (%)---17.09%-99.02%-79.87%+1649.64%+1920.53%-63.86%
Cost of Revenue451301520--37.30K188.60K1.14M
Gross Profit-451508.68K421.48K4.12K830-22.78K104.82K-1.04M
Gross Margin-99.94%99.88%100.00%100.00%-156.88%35.72%-977.06%
Operating Expense1.17M2.52M3.28M3.36M6.86M3.90M2.97M2.07M
Operating Income-1.17M-2.01M-2.86M-3.36M-6.86M-3.93M-2.87M-3.10M
Operating Margin--394.51%-678.15%-81410.81%-826956.63%-27045.99%-976.65%-2925.61%
EBITDA-1.17M-2.01M-2.86M-4.86M-6.81M-1.17M-2.86M-3.10M
EBITDA Margin--394.35%-677.85%-117954.75%-820996.75%-8040.75%-973.71%-2921.29%
Net Income-725.26K-1.50M-2.44M-3.80M-6.80M-1.18M-2.63M-3.06M
Net Income Margin--294.41%-577.97%-92054.07%-819526.75%-8097.12%-897.83%-2889.11%
R&D1.06M1.63M1.13M2.22M4.09M1.91M735.20K549.25K
R&D as % of Total Revenue-320.00%268.86%53769.23%492845.30%13119.47%250.56%518.02%
Interest Expense0004.14K-1.01K9.18K-
Interest Expense % of Total Revenue-0.00%0.00%100.48%-6.93%3.13%-

Balance Sheet

Currency: AUD2019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Total Assets1.18M654.81K11.77M8.73M2.98M2.41M1.83M2.17M
Total Liabilities97.61K264.22K214.80K450.10K506.44K291.07K271.28K483.03K
Total Equity1.08M390.60K11.55M8.28M2.48M2.12M1.56M1.68M
Cash577.46K92.70K10.88M7.14M2.35M824.78K983.35K1.32M
Total Debt54.41K54.41K------
Net Debt-523.05K-38.29K-10.88M-7.14M-2.35M-824.78K-983.35K-1.32M

Cash Flow

Currency: AUD2019-06-302020-06-302021-06-302022-06-302023-06-302024-06-302025-06-302026-06-30
Operating Cash Flow-1.06M-985.01K-1.94M-4.20M-5.78M-2.34M-1.78M-2.60M
Investing Cash Flow--16.07K-16.07K-32.54K-1.62K-134-82.98K-
Financing Cash Flow1.26M500.25K3.01M10.23M996.65K815.21K2.02M2.94M
Capital Expenditure016.07K16.07K32.54K1.62K13482.98K5
Free Cash Flow-1.06M-985.01K-1.95M-4.23M-5.78M-2.35M-1.86M-2.60M
FCF to OCF100.00%100.00%100.83%100.77%100.03%100.01%104.66%100.00%

Earnings

Report DateJan 25, 2022Aug 23, 2022Feb 17, 2023Feb 20, 2025Aug 29, 2025
EPS Estimate0.000.000.000.000.00
EPS Actual-0.01-0.04-0.02-0.01-0.01
Surprise-----
Timing-----

Key Statistics & Ratios

Market Cap8.04M
Enterprise Value6.43M
Trailing P/E0.00
Forward P/E0.00
PEG Ratio0.00
Price / Sales59.30
Price / Book4.61
EPS-0.01
Book Value0.006
Revenue (TTM)135.62K
Gross Profit (TTM)-33.92K
EBITDA-2.97M
Profit Margin0.00%
Operating Margin-4041.53%
Return on Equity-189.19%
Return on Assets-92.99%
Shares Outstanding287.20M
Shares Float157.32M
Beta0.85
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%